CLIN CANCER RES：针对卵巢癌TP53“热点突变”及特异性新抗原的T细胞反应

2018-11-21 MedSci MedSci原创

CLIN CANCER RES近期发表了一篇文章，评估转移性卵巢癌患者肿瘤中针对自体体细胞突变新抗原的T细胞反应。

CLIN CANCER RES近期发表了一篇文章，评估转移性卵巢癌患者肿瘤中针对自体体细胞突变新抗原的T细胞反应。

作者扩增了切除后的转移性卵巢癌病灶中的肿瘤浸润淋巴细胞（TIL），通过全外显子和转录组测序分析鉴定自体体细胞突变。在自体抗原呈递细胞中表达所有突变的新表位，然后与TIL共培养。IFNγ分泌或41BB的上调表明存在T细胞反应。研究对 7名转移性卵巢癌患者进行了评估，5名患者出现对突变新抗原显着的T细胞反应，且通过与野生型序列比较，最小表位的鉴定，人白细胞抗原（HLA）限制性因素和新抗原特异性T细胞受体等得到验证。突变的新抗原受HLA-B，-C，-DP，-DQ和/或-DR等位基因的限制，且来自每个患者独有的随机体细胞突变。作者发现两个不同患者肿瘤表达的TP53 "热点"突变（c.659A> G； p.Y220C和c.733G> A； p.G245S）均具有免疫原性。

文章最后认为，突变反应性T细胞在卵巢癌转移灶中存在充分浸润，为其作为过继细胞疗法进行后续研究提供了基础。此外，TP53 "热点"突变 - 反应性T细胞受体向外周血T细胞的转移可以作为多种肿瘤基因疗法。

原始出处：

Drew C. Deniger, Anna Pasetto, et al. T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. CLIN CANCER RES. November 2018 doi: 10.1158/1078-0432.CCR-18-0573

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2019-07-13 millore

#T细胞反应#

43 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-30 jjjiang0199

#热点突变#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2019-02-03 jinweidong

#特异性#

40 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-23 zhishijing

#p53#

38 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-23 zblhy

#TP53#

43 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-23 xiaoyeshuang

#抗原#

0 0
[GetPortalCommentsPageByObjectIdResponse(id=1649527, encodeId=bd59164952e36, content=<a href='/topic/show?id=5b05180159a' target=_blank style='color:#2F92EE;'>#T细胞反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18015, encryptionId=5b05180159a, topicName=T细胞反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cce623855314, createdName=millore, createdTime=Sat Jul 13 07:40:00 CST 2019, time=2019-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061265, encodeId=0465206126533, content=<a href='/topic/show?id=63976e22482' target=_blank style='color:#2F92EE;'>#热点突变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67224, encryptionId=63976e22482, topicName=热点突变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5319428, createdName=jjjiang0199, createdTime=Fri Nov 30 06:40:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899255, encodeId=044e189925565, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Sun Feb 03 21:40:00 CST 2019, time=2019-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372405, encodeId=39a613e240557, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458442, encodeId=68db145844221, content=<a href='/topic/show?id=50a81e6869e' target=_blank style='color:#2F92EE;'>#TP53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17686, encryptionId=50a81e6869e, topicName=TP53)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2d276073420, createdName=zblhy, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623314, encodeId=3255162331471, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Fri Nov 23 11:40:00 CST 2018, time=2018-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353321, encodeId=f6c035332104, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu Nov 22 07:46:49 CST 2018, time=2018-11-22, status=1, ipAttribution=)]
2018-11-22 kafei

学习了谢谢

67 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

肿瘤科

CLIN CANCER RES：针对卵巢癌TP53“热点突变”及特异性新抗原的T细胞反应

相关资讯

科室

工具

服务